Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clinical Groups Call For 'Me-Too' Pathway For Infectious Disease LDT Approvals

This article was originally published in The Gray Sheet

Executive Summary

A group of infectious disease and clinical virology societies are asking FDA to establish an alternative under the agency's proposed lab-developed test framework for infectious disease test services. Clinical laboratories should be able to use commercial high-risk tests as predicates for ID LDTs so they won't have to go through the costly PMA submissions process.

You may also be interested in...



FDA Plan To Regulate LDTs Includes Long Phase-In, Unmet-Need Exceptions

FDA said its new plan, which can’t be released as a formal draft guidance for another 60 days, would establish a more level playing field between test-kit makers and labs, while being flexible when there is not an FDA-approved alternative to an lab-developed test.

Teva Appoints Former Sandoz CEO Francis To Replace Schultz

Teva will soon have a new president and CEO with former Sandoz chief Richard Francis announced as Kåre Schultz’s replacement from the start of 2023.

More Than 50% Of EU Clinicians Report Recent Medical Device Shortages

Shortages of medical devices ranging from insulin pumps to robotic surgical systems are impacting clinicians across the EU, leaving many healthcare providers without effective alternative products, a report by the Biomedical Alliance in Europe shows.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT034712

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel